These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15344542)

  • 21. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
    Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
    J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of severe gastroesophageal reflux disease.
    DiPalma JA
    J Clin Gastroenterol; 2001 Jan; 32(1):19-26. PubMed ID: 11154163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications.
    Richter JE
    Am J Gastroenterol; 2000 Feb; 95(2):368-73. PubMed ID: 10685737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helicobacter pylori infection prevents nocturnal gastric acid breakthrough.
    Saiki Y; Yoshida T; Tanioka Y; Yagawa T; Harada T; Okazawa T; Okita K
    Hepatogastroenterology; 2006; 53(67):150-4. PubMed ID: 16506396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2C19 polymorphism and proton pump inhibitors.
    Klotz U; Schwab M; Treiber G
    Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel endoscopic submucosal dissection technique for proton pump inhibitor-refractory gastroesophageal reflux disease.
    Ota K; Takeuchi T; Harada S; Edogawa S; Kojima Y; Inoue T; Higuchi K
    Scand J Gastroenterol; 2014 Dec; 49(12):1409-13. PubMed ID: 25384555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe reflux esophagitis.
    Richter JE
    Gastrointest Endosc Clin N Am; 1994 Oct; 4(4):677-98. PubMed ID: 7812641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
    Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
    J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of wireless pH monitoring technologies: a summary of the proceedings from the esophageal diagnostic working group.
    Richter JE; Pandolfino JE; Vela MF; Kahrilas PJ; Lacy BE; Ganz R; Dengler W; Oelschlager BK; Peters J; DeVault KR; Fass R; Gyawali CP; Conklin J; DeMeester T;
    Dis Esophagus; 2013; 26(8):755-65. PubMed ID: 22882487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cause and prevention of nocturnal gastric acid breakthrough].
    Adachi K; Kinoshita Y
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
    [No Abstract]   [Full Text] [Related]  

  • 31. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?
    Beaumont H; Boeckxstaens GE
    Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Obesity and gastroesophageal reflux disease].
    Gómez Escudero O; Herrera Hernández MF; Valdovinos Díaz MA
    Rev Invest Clin; 2002; 54(4):320-7. PubMed ID: 12415956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
    Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
    Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroesophageal reflux disease.
    Williams CN
    Can J Gastroenterol; 1998 Mar; 12(2):107-8. PubMed ID: 9559205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary care for GEDR].
    Takeda H
    Nihon Rinsho; 2004 Aug; 62(8):1499-503. PubMed ID: 15344540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic approaches to reflux disease, focusing on acid secretion.
    Kinoshita Y; Adachi K; Fujishiro H
    J Gastroenterol; 2003 Mar; 38 Suppl 15():13-9. PubMed ID: 12698865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology.
    Bhatia SJ; Makharia GK; Abraham P; Bhat N; Kumar A; Reddy DN; Ghoshal UC; Ahuja V; Rao GV; Devadas K; Dutta AK; Jain A; Kedia S; Dama R; Kalapala R; Alvares JF; Dadhich S; Dixit VK; Goenka MK; Goswami BD; Issar SK; Leelakrishnan V; Mallath MK; Mathew P; Mathew P; Nandwani S; Pai CG; Peter L; Prasad AVS; Singh D; Sodhi JS; Sud R; Venkataraman J; Midha V; Bapaye A; Dutta U; Jain AK; Kochhar R; Puri AS; Singh SP; Shimpi L; Sood A; Wadhwa RT
    Indian J Gastroenterol; 2019 Oct; 38(5):411-440. PubMed ID: 31802441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative pharmacology of proton pump inhibitors.
    Barone JA; Horn JR
    Manag Care; 2001 Oct; 10(10 Suppl):11-6. PubMed ID: 11729442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of esophageal motility and hiatal hernia in esophageal exposure to acid.
    Xenos ES
    Surg Endosc; 2002 Jun; 16(6):914-20. PubMed ID: 12163954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors.
    Fouad YM; Katz PO; Castell DO
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1467-71. PubMed ID: 10571603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.